|
Key
Features: |
|
| Title and year of the Document | Pharmaceutical Economic Evaluation Guidelines (January 2006) |
| Affiliation of authors | |
| Main policy objective | |
| Standard reporting format included | |
| Disclosure | |
| Target audience of funding/ author’s interests | |
| Perspective | |
| Indication | |
| Target population | |
| Subgroup analysis | |
| Choice of comparator | |
| Time horizon | |
| Assumptions required | |
| Preferred analytical technique | |
| Costs to be included | |
| Source of costs | |
| Modeling | |
| Systematic review of evidences | |
| Preference for effectiveness over efficacy | |
| Preferred outcome measure | |
| Preferred method to derive utility | |
| Equity issues stated | |
| Discounting costs | |
| Discounting outcomes | |
| Sensitivity analysis-parameters and range | |
| Sensitivity analysis-methods | |
| Presenting results | |
| Incremental analysis | |
| Total C/E | |
| Portability of results (Generalizability) | |
| Financial impact analysis | |
| Mandatory or recommended or voluntary | |
